drugset / Trial / NCT01253694

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

NCT01253694

Phase 2 Withdrawn New England Retina Associates
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Treatment with Ranibizumab of the residual diabetic edema in patients with failed response to Bevacizumab.

Timeline

Start
2011-03
Primary completion
2012-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal